Indeed, isolated and enriched CTCs from CRC patients have been used to detect KRAS and BRAF mutations [69] showing 70% similitude in the KRAS mutation state compared to their primary tumors [69,70], but less consistent results in BRAF mutations [70]. This evidence concerns the gene BRAF and colorectal carcinoma.